J&J/Centocor’s Remicade Gains Pediatric Crohn’s Disease Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
Remicade is the first Crohn's disease therapy approved for pediatric patients following its May 19 supplemental BLA approval
You may also be interested in...
Humira Clears FDA As First Self-Administered Biologic For Crohn’s Disease
Abbott’s adalimumab will compete with Johnson & Johnson’s Remicade in the Crohn’s market following approval of an sBLA for the indication.
Humira Clears FDA As First Self-Administered Biologic For Crohn’s Disease
Abbott’s adalimumab will compete with Johnson & Johnson’s Remicade in the Crohn’s market following approval of an sBLA for the indication.
J&J/Centocor Seek To Expand Remicade Psoriatic Arthritis Indication
sBLA for the arthritis medication seeks to add inhibition of disease progression to labeling.